Johnson & Johnson MedTech introduces automated system for surgical efficiency
This tool aims to minimise the physical strain on surgeons during the procedures.
It is designed to offer control and alleviate the load associated with manual impaction in primary and revision hip surgeries, as well as revision knee replacement surgeries.
The company noted that surgeons in the field of orthopaedics are increasingly confronted with complex challenges in the operating room such as longer procedures, the physical demands of surgery, and higher case volumes.
KINCISE 2 aims to address the issues of monotonous, high-force tasks, including repeated mallet strikes, which have been associated with overuse injuries, with the majority of surgeons reporting musculoskeletal pain, especially in their hands, neck, and lower back.
Building on the company's first-generation KINCISE System, the new system features design elements such as increased reverse energy to aid in broach removal and push-to-lock adaptors to facilitate secure connections.
According to the company, the Acetabular Cup Extraction addition positions the system as the first and only automated surgical impactor approved for the removal of well-fixed acetabular components, thereby widening its utility in complex hip revisions.
Currently available for commercial use in the US, the system is equipped with a compact design and several grip options.
Johnson & Johnson MedTech Orthopaedics company group chair Aldo Denti said: 'The KINCISE 2 System exemplifies the needs-based innovation we're bringing to orthopaedics this year.
'As more patients undergo joint replacements earlier in life, the demand for revision surgeries is rising. The KINCISE System has demonstrated the ability to help surgeons manage those complex cases by reducing operating time and providing procedural control - ultimately supporting better outcomes for patients.'
Last month, the company launched the Soundstar Crystal ultrasound catheter in the US, which is intended for use in intracardiac echocardiography imaging during cardiac ablation procedures.
"Johnson & Johnson MedTech introduces automated system for surgical efficiency" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Opendoor stock pops 10% as company says CEO will step down
Opendoor Technologies (OPEN) shares spiked as 8% in early trading Friday after the company announced that CEO Carrie Wheeler will step down, effective immediately. The company's board appointed Opendoor's chief technology and product officer Shrisha Radhakrishna as president and interim leader of the company. Opendoor, which uses iBuyer real estate technology to flip homes, said it was searching for a new CEO. Since going public through a SPAC transaction in 2020, Opendoor has yet to post a profitable quarter. The company received a warning in May that it faced potential delisting from the Nasdaq after trading under $1 for more than 30 days. Shares have surged more than 200% in the past month, powered in part by Carvana (CVNA) turnaround spotter EMJ Capital and speculative investors on Reddit's wallstreetbets, a haven for meme stocks. EMJ Capital founder and president Eric Jackson said in an X post on July 14 that his firm was taking a long position in Opendoor, which was then trading under $1 per share. "The communication on the earnings call from the CEO and the CFO was really awful," Jackson told Yahoo Finance last week. Jackson has been critical of Opendoor's top leadership, most recently following the company's latest quarterly results in early August, when the stock sank 20% following disappointing earnings forecast. Year-to-date Opendoor shares are up 100%. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Flowers Foods Trims Annual Outlook As Bread Demand Softens
Flowers Foods, Inc. (NYSE:FLO) shares are trading lower on Friday. The company reported a second-quarter adjusted earnings per share of 30 cents, which is in line with the analyst consensus estimate. Quarterly sales of $1.242 billion (+1.5% year over year) missed the Street view of $1.266 billion. 'Macroeconomic uncertainty and shifting consumer demand have continued to pressure the bread category,' said Ryals McMullian, chairman and CEO of Flowers decreased 1.2% in the quarter under review, while volume declined 2.4%. Net income decreased 12.8% to $58.4 million, representing 4.7% of sales, an 80-basis point decrease, primarily due to greater outside purchases, increased workforce-related costs, and higher interest expense. Adjusted net income decreased 16% to $63.4 million. View more earnings on FLO Adjusted EBITDA decreased 4% to $137.7 million. Adjusted EBITDA margin was 11.1% of net sales, down 60 basis points. 'We are proactively working to mitigate this weakness with disciplined cost savings efforts,' the CEO added. Simple Mills contributed $61.4 million in net sales, with a net loss of $2.1 million. The company exited the quarter with cash and equivalents worth $11.045 million. Long-term debt as of quarter-end expanded to $1.749 billion, compared with $1.021 billion as of December 28, 2024. Outlook Flowers Foods cut its FY2025 adjusted EPS forecast to $1.00–$1.10, down from its prior view of $1.05–$1.15. The revised outlook compares with the consensus estimate of $1.09. The company also lowered its FY2025 sales guidance to a range of $5.021 billion–$5.083 billion from $5.079 billion–$5.170 billion. This new sales forecast falls short of the Street's expectation of $5.310 billion. Price Action: FLO shares are trading lower by 2.63% to $16.11 at last check Friday. Read Next:Photo by Kritchai7752 via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Flowers Foods Trims Annual Outlook As Bread Demand Softens originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
